Pursuant to the approval granted by the shareholders vide postal ballot on 5th September , 2018, Glaxosmithkline Pharmaceuticals has informed that as authorized by Board the meeting of Managing Director, Whole-time Director and Company Secretary held on 14th September 2018, has approved the allotment of 8,47,03,017 fully paid-up bonus equity shares to the existing shareholders in the ratio of one bonus equity share of face value Re 10 each credited as fully paid up for every one equity shares of face value Re 10 each held on the Record date viz. 13th September 2018. The post issued paid up capital of the Company is now Rs 169,40,60,340.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: